Esteghamati, A. and Rajabian, R. and Amini, M. and Bahrami, A. and Khamseh, M.E. and Afkhami-Ardekani, M. and Rizi, E.P. (2010) The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: An open-label, non-randomised, multi-centre observational study - The Iran subgroup of the IMPROVE� study. Endokrynologia Polska, 61 (4). pp. 364-370.
Full text not available from this repository.Abstract
Introduction: To evaluate the clinical profile of BIAsp 30 (30 soluble insulin aspart, 70 protamine-crystallized insulin aspart) (NovoMix®30) in type 2 diabetes patients in routine clinical practice in Iran. Material and methods: IMPROVE� was a 26-week, multinational, open-label, non-randomized study in patients with type 2 diabetes. The safety and efficacy of BIAsp 30 were assessed at baseline and at 13 and 26 weeks. The titration of BIAsp30 was at the physician's discretion. Results: In Iran, 478 patients (47 male) previously treated with oral antidiabetic drugs (OADs) (N = 159, 33.3) and/or insulin other than BIAsp30 (N = 317, 66.3) or a few who were treatment-naive (N = 2, 0.4) participated in the study. After 26 weeks of treatment with BIAsp 30, the rate of reported major hypoglycaemic episodes was reduced by 88.1 from baseline (baseline v. Week 26: 0.303 v. 0.037 episodes/pt-year; p < 0.001). No significant differences in minor hypoglycaemic episodes between baseline and Week 26 were found. Glycaemic control was significantly improved from baseline to Week 26 with a mean HbA1c reduction of 1.2 ± 1.9. Patients' quality of life as measured by the DiabMedSat questionnaire significantly improved from baseline (58.1) to the end of the study (75.4, p < 0.001). Conclusions: BIAsp 30 therapy appeared safe and effective and improved quality of life in Iranian patients with type 2 diabetes after 26 weeks of treatment.
| Item Type: | Article |
|---|---|
| Additional Information: | cited By 9 |
| Uncontrolled Keywords: | insulin; insulin aspart; oral antidiabetic agent, adult; aged; article; clinical assessment; clinical practice; clinical trial; controlled clinical trial; controlled study; drug dose titration; drug efficacy; drug safety; female; glycemic control; human; hypoglycemia; Iran; major clinical study; male; multicenter study; non insulin dependent diabetes mellitus; observational study; open study; quality of life; questionnaire; treatment duration, Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Iran; Male; Middle Aged; Quality of Life |
| Subjects: | WD Disorders of Systemic, Metabolic or Environmental Origin, etc. WK Endocrine System |
| Depositing User: | s shekarchi shekarchi |
| Date Deposited: | 10 Oct 2021 06:11 |
| Last Modified: | 10 Oct 2021 06:11 |
| URI: | http://eprints.iums.ac.ir/id/eprint/21241 |
Actions (login required)
 |
View Item |
